WebPRRT (Lutathera) is an FDA-approved treatment for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). ... (Lutathera) have somatostatin receptor-positive GEP-NETS. The tumors have responded to somatostatin analogue (SSA) therapy (octreotide, lanreotide, etc.) in the past. However, despite continued SSA therapy, … WebApr 13, 2024 · This is a multicenter, open-label, single-arm study to evaluate the safety and dosimetry of Lutathera in adolescent patients 12 to <18 years old with somatostatin receptor positive GEP-NETs and PPGLs. The study will enroll at least 8 patients in the GEP-NET cohort and as many adolescents with PPGL as possible in the exploratory PPGL …
NCT04946305 Novartis
WebPeptide receptor radionuclide therapy (PRRT) using Lutetium-177 (177Lu) based radiopharmaceuticals has emerged as a therapeutic area in the field of nuclear medicine and oncology, allowing for personalized medicine. Since the first market authorization in 2024 of [¹⁷⁷Lu]Lu-DOTATATE (Lutathera®) targeting somatostatin receptor type 2 in the … WebLUTATHERA® (lutetium Lu 177 dotatate) is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS are kim and kanye dating
FDA approves new treatment for certain digestive tract
WebFeb 11, 2024 · The product, 177 Lu-dotatate ( Lutathera, Advanced Accelerator Applications), is a peptide receptor radionuclide therapy that is the first agent in its class. It was approved for the treatment of adult patients with somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). These tumors can occur in … WebOn January 26, 2024, the Food and Drug Administration approved lutetium Lu 177 dotatate (LUTATHERA, Advanced Accelerator Applications USA, Inc.) a radiolabeled somatostatin analog, for the ... WebLUTATHERA ® 370 MBq/mL solution for infusion is a radiolabeled somatostatin analogue (SSA) comprised of the radionuclide lutetium-177 and the peptide oxodotreotide. 1,2 It is designed to deliver beta radiation directly to gastroenteropancreatic neuroendocrine tumor (GEP-NET) cells, disrupting them from within: 1. bakugan battle brawlers ps2 guide